Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients.
Abnormal DNA methylation is a feature of most types of cancer, which is reflected in cell-free circulating DNA in plasma. It is, however, unknown whether surgical removal of the tumor and subsequent therapy induces changes in plasma DNA methylation, which can be used to monitor treatment. In this pilot study, methylation in cell-free plasma DNA of 20 breast cancer patients was determined by the previously developed MethDet-56 technique. Samples at three time points were analyzed-before surgery (baseline), after surgery (to evaluate the effects of resection) and after surgery on tamoxifen therapy (to determine the effects of treatment). Methylation patterns of healthy controls were used as a reference for all comparisons. Seven promoters were differentially methylated (p < 0.05) in at least one comparison; three changed after surgery; another one changed after beginning of tamoxifen treatment; and four were differentially methylated in baseline versus combined treatment samples. Increased methylation of PR PROX, MDGI, PAX 5 and RARβ2 at baseline (presurgery) diminished toward the healthy controls with the lowest methylation in the combined treatment group. Surgery alone decreased methylation in PAX 5 and RARβ2, whereas tamoxifen treatment changed methylation only in the B promoter of ESR1. Methylation patterns in cell-free plasma DNA change after surgery and tamoxifen treatment, most significantly-after combined treatment. The baseline (presurgery) patterns become similar to those of healthy controls, suggesting that methylation patterns in cell-free plasma DNA may be used to monitor treatment.
Liggett
Thomas E
TE
Department of Neurology, Rush University Medical Center, Chicago, IL, USA.
Melnikov
Anatoliy A
AA
Marks
Jeffrey R
JR
Levenson
Victor V
VV
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000235:genetics*; D011401:Promoter Regions, Genetic; D013629:Tamoxifen / Q000627:therapeutic use
D004273:DNA, Neoplasm; D013629:Tamoxifen
Br J Haematol. 1994 Apr;86(4):774-9
7918071
J Mol Diagn. 2008 Jan;10(1):93-101
18165279
Clin Cancer Res. 2009 Feb 15;15(4):1184-91
19228724
Endocrine. 2000 Aug;13(1):1-10
11051041
Cancer Res. 1996 Nov 1;56(21):4865-70
8895735
Ann Oncol. 2000 Sep;11(9):1097-104
11061602
J Cell Sci. 2008 Oct 1;121(Pt 19):3146-54
18765568
Br J Cancer. 1997;76(10):1293-9
9374374
J Mol Diagn. 2009 Jan;11(1):60-65
19074590
Int J Cancer. 2003 Jun 20;105(3):361-70
12704670
Br J Cancer. 2009 Apr 21;100(8):1277-86
19367284
Ann N Y Acad Sci. 2001 Dec;949:72-9
11795383
Gastroenterology. 1997 Apr;112(4):1114-20
9097993
Mol Oncol. 2008 Jun;2(1):33-40
19383327
Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R50-9
17613547
J Surg Oncol. 2009 Feb 1;99(2):119-22
19065635
Mod Pathol. 2007 Jul;20(7):711-21
17464311
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Cancer Biol Ther. 2008 Jun;7(6):958-65
18379196
Gynecol Oncol. 2004 May;93(2):435-40
15099958
Clin Cancer Res. 2004 Dec 15;10(24):8152-62
15623589
Ann N Y Acad Sci. 2004 Jun;1022:44-9
15251938
Carcinogenesis. 2000 Dec;21(12):2193-201
11133808
Ann N Y Acad Sci. 2000 Apr;906:25-8
10818591
Clin Cancer Res. 1998 Feb;4(2):271-5
9516910
Oncogene. 2000 Mar 16;19(12):1556-63
10734315
Br J Cancer. 2006 May 22;94(10):1492-5
16641902
Cancer Res. 2001 Apr 1;61(7):3105-9
11306494
Nat Med. 1996 Sep;2(9):1033-5
8782463
Ann N Y Acad Sci. 2000 Apr;906:5-7
10818586
Genes Chromosomes Cancer. 1999 Feb;24(2):160-1
9885984
Cancer Res. 2003 Mar 1;63(5):1114-21
12615730
Ann Oncol. 1998 Jan;9(1):113-6
9541693
Int J Cancer. 2003 Jan 10;103(2):149-52
12455027
Cancer Res. 1999 Jan 1;59(1):67-70
9892187
Cancer. 2010 Apr 1;116(7):1674-80
20143430
J Neurol Sci. 2010 Mar 15;290(1-2):16-21
20064646
Cancer Res. 2003 Aug 1;63(15):4620-5
12907641
Br J Cancer. 1999 Jun;80(8):1262-4
10376981
Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):67-71
8118388
J Clin Oncol. 2000 Sep;18(17):3172-86
10963646
Mol Endocrinol. 2001 Dec;15(12):2057-63
11731608
Oncogene. 2002 Aug 12;21(35):5462-82
12154408
Ann Surg Oncol. 2002 Jan-Feb;9(1):71-6
11829433
Cancer Res. 2002 Jan 15;62(2):371-5
11809682
Cancer Res. 1994 May 15;54(10):2552-5
8168078
Nucleic Acids Res. 2005 Jun 08;33(10):e93
15944447
Adv Cancer Res. 1998;72:141-96
9338076
Cancer Res. 1998 Jun 15;58(12):2515-9
9635570
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6189-93
15448006
Ann N Y Acad Sci. 2004 Jun;1022:17-24
15251934
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3036-43
19861523
Cancer Res. 2005 Feb 15;65(4):1141-5
15734995
Semin Oncol. 2001 Jun;28(3):260-73
11402436
Clin Cancer Res. 1996 May;2(5):805-10
9816234
Ann N Y Acad Sci. 2000 Apr;906:72-82
10818600
J Mol Med (Berl). 2005 Feb;83(2):132-9
15536519
J Clin Oncol. 2006 Sep 10;24(26):4262-9
16908936
Lancet. 1998 Sep 19;352(9132):930-42
9752815